Sernova (TSE:SVA) Trading 22.7% Higher – Still a Buy?

Sernova Corp. (TSE:SVA)’s share price traded up 22.7% during trading on Tuesday . The stock traded as high as C$0.14 and last traded at C$0.14. Approximately 1,095,695 shares were traded during trading, an increase of 820% from the average session volume of 119,128 shares. The stock had previously closed at C$0.11.

Sernova Stock Performance

The company has a debt-to-equity ratio of -25.45, a quick ratio of 18.11 and a current ratio of 0.14. The stock has a fifty day simple moving average of C$0.11 and a two-hundred day simple moving average of C$0.14. The stock has a market cap of C$52.87 million, a PE ratio of -3.50 and a beta of -0.43.

Sernova (TSE:SVA) last posted its quarterly earnings data on Thursday, June 11th. The company reported C$0.01 earnings per share (EPS) for the quarter. Equities analysts anticipate that Sernova Corp. will post -0.08 EPS for the current fiscal year.

About Sernova

Sernova Biotherapeutics is a clinical-stage company developing regenerative medicine therapeutics combining its Cell Pouch with human donor cells or stem-cell derived islet-like clusters in collaboration with Evotec to create bio-hybrid organs to treat T1D. A bio-hybrid organ is comprised of non-biomaterials, such as the Cell Pouch, integrated with living tissues to restore or enhance the function of a compromised organ. This innovative approach aims to deliver a potentially revolutionary treatment for patients with chronic diseases, initially focusing on T1D and thyroid disorders.